바이오의약품 발효 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Biopharmaceutical Fermentation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1668177
리서치사:TechSci Research
발행일:2025년 02월
페이지 정보:영문 187 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 바이오의약품 발효 시장 규모는 2024년에 250억 6,000만 달러로, 예측 기간 중 CAGR은 8.43%로 2030년에는 408억 2,000만 달러에 달할 것으로 예측됩니다.
COVID-19는 바이오의약품 발효 시장의 성장에 영향을 미쳤습니다. 팬데믹은 혁신적인 현장 진단 키트와 mRNA 백신에 필수적인 효소에 대한 전례 없는 수요를 불러일으켰습니다. 따라서 기업 활동의 활성화와 생명공학 기반 의약품에 대한 수요 증가 등의 요인으로 인해 예측 기간 중 이 시장은 성장할 것으로 예상됩니다. 그러나 바이오의약품 발효의 높은 도입 비용은 예측 기간 중 바이오의약품 발효 시장의 성장을 저해할 가능성이 높습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
250억 6,000만 달러
시장 규모 : 2030년
408억 2,000만 달러
CAGR: 2025-2030년
8.43%
급성장 부문
다운스트림 제품
최대 시장
북미
시장 성장 촉진요인
바이오의약품 파이프라인의 성장
주요 시장이 해결해야 할 과제
규제의 복잡성
주요 시장 동향
연속 발효에 집중
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 바이오의약품 발효 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
제품 유형별(업스트림 제품, 다운스트림 제품)
용도별(항생제, 재조합 단백질, 기타)
최종사용자별(바이오의약품 산업, 계약 조사기관, 학술 조사기관, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 바이오의약품 발효 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
캐나다
멕시코
제7장 유럽의 바이오의약품 발효 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 바이오의약품 발효 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
인도
일본
한국
호주
제9장 남미의 바이오의약품 발효 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 바이오의약품 발효 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병과 인수(있는 경우)
제품의 발매(있는 경우)
최근 동향
제13장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Agilent Technologies, Inc.
Eppendorf SE
Thermo Fisher Scientific Inc.
c-LEcta GmbH
Sartorius AG
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Nova Biomedical Corporation
Concord Biotech Limited
Solaris Biotechnolgy Srl
제15장 전략적 제안
제16장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
Global Biopharmaceutical Fermentation Market was valued at USD 25.06 Billion in 2024 and is expected to reach USD 40.82 Billion by 2030 with a CAGR of 8.43% during the forecast period. COVID-19 has impacted the growth of the biopharmaceutical fermentation market. The pandemic resulted in an unprecedented demand for enzymes essential for innovative point-of-care diagnostic kits and mRNA vaccines. Therefore, owing to the factors, such as the rising company activities and increasing demand for biotech-based drugs, the studied market is anticipated to grow over the forecast period. However, the high cost of biopharmaceutical fermentation and installation is likely to impede the growth of the biopharmaceutical fermentation market over the forecast period.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 25.06 Billion
Market Size 2030
USD 40.82 Billion
CAGR 2025-2030
8.43%
Fastest Growing Segment
Downstream Products
Largest Market
North America
Key Market Drivers
Growing pipeline of biopharmaceuticals
The dominant driver for the Biopharmaceutical Fermentation market is the growing pipeline of biopharmaceuticals. This trend is driven by several key factors that highlight its centrality to the market: Biopharmaceuticals offer innovative solutions for a wide range of diseases, including cancer, autoimmune disorders, and rare diseases. The expanding therapeutic landscape necessitates the development of new biopharmaceuticals, fueling the pipeline. Biologics, a subset of biopharmaceuticals, are gaining prominence due to their specificity and effectiveness. As research uncovers new targets and mechanisms of action, biologics with diverse applications are being developed. The emergence of biosimilars, which are highly similar to approved biopharmaceuticals, but often more cost-effective, contributes to the growing pipeline. These products aim to provide affordable alternatives to existing biopharmaceuticals. In October 2022, Froilabo (Japan) introduced a new line of completely automated lab-scale bioreactors. The bioreactors, which complement their line of temperature-controlled laboratory equipment, provide a wide range of application possibilities for academics, research, process development and optimization, scale-up, and manufacturing.
Key Market Challenges
Regulatory complexities
Regulatory complexities represent a key challenge for the Biopharmaceutical Fermentation market due to the intricate and stringent requirements imposed by regulatory authorities worldwide. Several factors contribute to these complexities: Biopharmaceutical products must meet exceptionally high safety and efficacy standards. Regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA), scrutinize every aspect of the manufacturing process, including fermentation, to ensure patient safety. Any deviation or inconsistency can lead to regulatory hurdles. Fermentation processes can exhibit inherent variability, which is a natural challenge when dealing with living organisms. Controlling and minimizing this variability to meet regulatory standards can be complex and resource-intensive. Regulatory authorities demand comprehensive validation of biopharmaceutical manufacturing processes, including fermentation. This entails extensive documentation, data collection, and adherence to strict protocols throughout the product's lifecycle. Regulatory frameworks are not static; they evolve over time. Keeping up with changing regulations, especially in different regions, poses a challenge for manufacturers aiming to ensure compliance with the latest standards.
Different countries have their own regulatory requirements, adding complexity for companies operating on a global scale. Harmonizing these requirements while meeting local standards is a formidable task. Ensuring consistent product quality is paramount. Manufacturers must implement rigorous quality control measures to comply with regulatory standards, which often necessitates substantial investments in infrastructure and technology. The regulatory approval process can be lengthy, leading to delays in bringing biopharmaceutical products to market. Navigating these timelines and securing approvals can be financially taxing. In summary, regulatory complexities in the Biopharmaceutical Fermentation market stem from the need to maintain the highest safety and efficacy standards while dealing with the inherent variability of living organisms. These complexities require significant expertise, resources, and a proactive approach to ensure compliance with evolving global regulations and to meet the demands of a highly regulated industry.
Key Market Trends
Focus on Continuous Fermentation
Continuous fermentation has emerged as a prominent trend in the Biopharmaceutical Fermentation market, revolutionizing the way biopharmaceuticals are produced. Unlike traditional batch processing, continuous fermentation involves the uninterrupted and ongoing production of biopharmaceuticals. This trend is gaining momentum for several compelling reasons: Continuous fermentation offers higher levels of efficiency by maximizing equipment utilization and reducing downtime between batches, resulting in increased productivity. Real-time monitoring and control in continuous processes enhance product consistency and reduce batch-to-batch variability, ensuring a high level of product quality. Continuous fermentation can lead to significant cost savings, including reduced labor and materials costs, making it an economically attractive option for manufacturers. This approach is flexible and can be adapted to various scales, from small laboratory setups to large-scale commercial production, allowing for seamless scalability. Continuous processes often generate less waste and require smaller volumes, aligning with sustainability goals and reducing the environmental footprint of biopharmaceutical production. In December 2022, MilliporeSigma acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the Breez. The acquisition assists the company to strengthen company's upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes from 2ml to 2000L with rapid lab-scale process development.
Key Market Players
Agilent Technologies, Inc.
Eppendorf SE
Thermo Fisher Scientific Inc.
c-LEcta GmbH
Sartorius AG
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Nova Biomedical Corporation
Concord Biotech Limited
Solaris Biotechnolgy Srl
Report Scope:
In this report, the Global Biopharmaceutical Fermentation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Biopharmaceutical Fermentation Market, By Product Type:
Upstream Products
Downstream Products
Biopharmaceutical Fermentation Market, By Application:
Antibiotics
Recombinant Proteins
Others
Biopharmaceutical Fermentation Market, By End User:
Biopharmaceutical Industries
Contract Research Organization
Academic Research Institutes
Others
Biopharmaceutical Fermentation Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Biopharmaceutical Fermentation Market.
Available Customizations:
Global Biopharmaceutical Fermentation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Biopharmaceutical Fermentation Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Upstream Products, Downstream Products)
5.2.2. By Application (Antibiotics, Recombinant Proteins, Others)
5.2.3. By End User (Biopharmaceutical Industries, Contract Research Organization, Academic Research Institutes, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Biopharmaceutical Fermentation Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Biopharmaceutical Fermentation Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Biopharmaceutical Fermentation Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Biopharmaceutical Fermentation Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. Europe Biopharmaceutical Fermentation Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Biopharmaceutical Fermentation Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. United Kingdom Biopharmaceutical Fermentation Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. Italy Biopharmaceutical Fermentation Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. France Biopharmaceutical Fermentation Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain Biopharmaceutical Fermentation Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. Asia-Pacific Biopharmaceutical Fermentation Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Biopharmaceutical Fermentation Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India Biopharmaceutical Fermentation Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. Japan Biopharmaceutical Fermentation Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Biopharmaceutical Fermentation Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Biopharmaceutical Fermentation Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. South America Biopharmaceutical Fermentation Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Biopharmaceutical Fermentation Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Argentina Biopharmaceutical Fermentation Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Colombia Biopharmaceutical Fermentation Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. Middle East and Africa Biopharmaceutical Fermentation Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Biopharmaceutical Fermentation Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Biopharmaceutical Fermentation Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. UAE Biopharmaceutical Fermentation Market Outlook
